Eli Lilly and Company (NYSE: LLY) said the U.S. Food and Drug Administration approved Olumiant (baricitinib) as a once-daily oral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE